Skip to content

Study · Randomized controlled trial · n = 9,340 · 2020

2 results

Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial.

Mosenzon O, Bain SC, Heerspink HJL, Idorn T, Mann JFE, Persson F, Pratley RE, Rasmussen S, Rossing P, von Scholten BJ, Raz I

Diabetes, obesity & metabolism7 Aug 2020Cited by 22 (Europe PMC)

PMID32618386 (opens in a new tab)PMCIDPMC7689857 (opens in a new tab)DOI10.1111/dom.14126 (opens in a new tab)PepBankPUB-32618386
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes and high cardiovascular risk, risks of cardiorenal events and death across UACR and eGFR subgroups were generally lower or similar with liraglutide versus placebo.

    In plain wordsIn adults with type 2 diabetes and high heart risk, liraglutide gave lower or similar heart, kidney and death risks than placebo.

    Peptide
    Liraglutide
    Outcome
    MixedCardiorenal events and death across baseline UACR and eGFR subgroups
    Study

    n = 9,340

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    up to 1.8 mg daily · 3.5 to 5 yearsAs given in this study (human).

    Source sentences

    Summary
    Across UACR and eGFR subgroups, risks of cardiorenal events and death were generally lower or similar with liraglutide versus placebo.
    1 context sentence
    Summary · context
    Patients with type 2 diabetes and high cardiovascular (CV) risk were randomized 1:1 to the glucagon-like peptide-1 analogue liraglutide (≤1.8 mg daily; n = 4668) or placebo (n = 4672) plus standard care and followed for 3.5 to 5 years.

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 02HumanNot a test of Liraglutide aloneRandomized controlled trialOther

    In adults with type 2 diabetes and high cardiovascular risk, increasing baseline UACR and decreasing eGFR were linked with higher risks of the primary outcome, heart failure hospitalization, a composite renal outcome and death. This is a prognostic association, not a liraglutide effect.

    In plain wordsIn adults with type 2 diabetes and high heart risk, worse baseline kidney test results were linked to higher heart, kidney and death risks.

    Peptide
    Liraglutide
    Outcome
    IncreaseAssociation of baseline UACR and eGFR with cardiorenal outcomes and death
    Study

    n: not reported in source

    Comparator
    Lower baseline UACR and higher baseline eGFR
    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    Increasing UACR and decreasing eGFR were linked with higher risks of the primary outcome, heart failure hospitalization, a composite renal outcome and death (P-values for the Cochran-Armitage test for trends were all <.0001).
    1 context sentence
    Summary · context
    Patients with type 2 diabetes and high cardiovascular (CV) risk were randomized 1:1 to the glucagon-like peptide-1 analogue liraglutide (≤1.8 mg daily; n = 4668) or placebo (n = 4672) plus standard care and followed for 3.5 to 5 years.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.